In the health insurance-enhanced medical system, the coverage rate for clinic-level medical institutions decreased from 57.9% in 2018 to 57.2% in 2019, and medical technology support took priority.
Under the Moon Jae-in care policy, which raises the coverage expansion to 70%, the health insurance coverage rate increased only 0.4 percentage points from 63.8% in 2018 to 64.2% in 2019.
President Moon said in his report on the 4th anniversary of 'Moon Jae-in Care' on the 12th, "Health insurance will serve as a catalyst for accelerating the development of medical technology, and we will do our best to catch both rabbits: securing the sustainability of health insurance and expanding coverage." , gave priority to 'medical technology support'.
The proportion of premiums paid by citizens in total health insurance income related to health insurance finance increased from 82.3% in 2014 to 86.3% in 2019, the opposition party announced on the same day.
After the transition from preventive medicine to health insurance from the medical insurance system, the health insurance finance was incorporated into the national financial system with a mandatory support of 20% of the expected premiums annually.
In February, when the corona vaccine was announced, the Ministry of Health and Welfare said, "Vaccination cost support is a temporary support given the COVID-19 disaster situation." said.
In July 2019, the government announced that it would invest 25.8 billion won by 2021 to promote the “AI-using new drug development platform construction project” in which six research teams composed of AI and new drug development experts and operating organizations participated.
In the 2019 'Strengthening of the Strategic R&D Investment for Biohealth' policy in 2019, the government will invest more than 4 trillion won annually by 2025 to maximize biohealth investment by reorganizing 10 areas linked with policies to ①source and base, ②pharmaceuticals. , ③Health care service, ④Industrial innovation and regulatory science were prioritized for investment strategy.
In particular, by expanding the fields of existing new drugs and stem cells to 'medicine' and 'regenerative medicine', he pointed out strategic investments in identifying new biotechnology drugs and candidate substances, supporting domestic clinical expansion, healthcare services, and building healthcare big data. Shortly thereafter, related stocks in this field soared.
Then, the company-led K-Quarantine came out.
Mooncare, whose policy goal is to reduce medical expenses by strengthening regular health checkups, accelerated the concentration of high-priced large hospitals, and the share of health insurance medical expenses in tertiary hospitals increased from 16.2% in 2017 before the policy to 18.1% in 2018, and increased to 17.5% in 2019 and 17.5% in 2019. It is 17.6% in 2020.
There are 42 large medical institutions with expensive medical equipment as of this year, accounting for 0.04% of the total medical institutions, and the share of medical expenses in clinic-level medical institutions decreased from 28.3% in 2017 to 27.7% in 2020.
Health Insurance’s finances, which were in a surplus at the time of the announcement of ‘injection of 30.6 trillion won over 5 years’ in August 2017, were converted to a deficit of 177.8 billion won in 2018, 2.824.3 trillion won in 2019, and 353.1 billion won in 2020.
As the three branches of preventive medicine and welfare bureaucratic companies that dominated the health insurance system became the main body of K quarantine, infectious disease experts became the periphery.